To read the full story, subscribe or sign in.

Preclinical and early clinical data indicate that EP-42675 is a potent anticoagulant

Aug. 14, 2009

No Comments

BioWorld Science Conferences Hematologic

Today's news in brief

BioWorld

BioWorld briefs for Dec. 6, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 6, 2023.

‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

BioWorld

For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...

Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

BioWorld

Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...

Japan approves first self-amplifying mRNA COVID-19 vaccine from CSL, Arcturus

BioWorld

In a global first, Japan's Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA)...

Upgrade your daily dose of biopharma and medtech news

Preclinical and early clinical data indicate that EP-42675 is a potent anticoagulant